Naltrexone LA is under clinical development by BioCorRx and currently in Phase I for Opium (Opioid) Addiction. According to GlobalData, Phase I drugs for Opium (Opioid) Addiction have a 74% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Naltrexone LA’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Naltrexone LA overview

Naltrexone is under development for the treatment of alcohol and opioid addiction. It is a long acting implantable naltrexone implant, administered by the subcutaneous route. It acts by targeting mu type opioid receptor.

BioCorRx overview

BioCorRx formerly Fresh Start Private Management, is a healthcare solution provider. The company offers alcoholism and opioid addiction treatment program for use in rehabilitation and treatment centers. It distributes and licenses BioCorRx recovery program, a medication-assisted treatment (MAT) program that includes a counseling program coupled with its proprietary naltrexone implant. It also develops BICX101, an injectable naltrexone product; and BICX102, an implantable naltrexone implant for the treatment of alcohol and opioid addiction. The company distributes its program to healthcare providers, independent licensed clinics and licensed healthcare professionals. BioCorRx is headquartered in Anaheim, California, the US.

For a complete picture of Naltrexone LA’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.